Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
Complete the form below to unlock access to ALL audio articles.
Interleukin Genetics, Inc. has announced the launch of an enhanced test report format and information package for the company's Heart Health Genetic Test. The test is currently marketed under the brand name Gensona® Heart Health Genetic Test by Quixtar/Amway.
The new report will include quantified risk information on heart attack and coronary artery disease generated from clinical studies and conducted by the company. The company believes that this enhanced report format will provide individuals and their physicians more complete information about a person's inflammation-based genetic risk factor for a heart attack.
The package also provides information on the science behind the genetic test and information to help people understand preventive measures and actions that can be taken to lower the risk of heart disease.
In addition, the company will conduct scientific lectures on the Gensona® test for interested Quixtar/Amway individual business owners at their scheduled conferences. The first of these lectures will be on Saturday morning and afternoon, July 26, 2008 at the Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel & Convention Center in Valley Forge, PA. Thousands of attendees are expected at the conference.
Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, "Heart disease is by far the leading killer of Americans. Individuals with different interleukin gene variations have vastly different clinical trajectories for heart disease progression. The ability to know your individual genetic predisposition for this disease is a new and powerful tool to allow a customer and their physicians to design the best preventive care for that person."
